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Objective:
 
 A patient-specific drug safety-efficacy index
was developed that combined objective clinical trial in-
formation about dose-related efficacy and toxicity with
subjective perspectives on efficacy-toxicity trades.
 
Methods:
 
 Patient preferences were systematically as-
sessed using the probability tradeoff technique (PTT).
Toxicity ranges over which a drug’s efficacy exceeded
the patient’s minimally acceptable efficacy represented
ranges of “surplus efficacy.” These can be related to the
dose interval in which a drug delivers this surplus effi-
cacy. Seventy surplus efficacy functions (for 7 hypothet-
ical drugs and 10 hypothetical preference curves) were
simulated.
 
Results:
 
 The analysis showed that index values change
markedly by dose and patient preference, suggesting
that different patients will benefit from different drugs
depending on the dose prescribed and each patient’s
subjective assessment of the efficacy/toxicity tradeoff.
In most situations, drugs achieve positive surplus effi-
cacy only over limited dose ranges. The model was sen-
sitive to different preference curves and discriminated
well among drugs with different efficacy or safety pro-
files.
 
Conclusion:
 
 This index provides a new, systematic ap-
proach to choosing a specific therapeutic intervention
and dosage, when known risks and benefits are recon-
ciled against patient-specific preferences among an ar-
ray of therapeutic alternatives.
 
Keywords:
 
 benefit-risk assessment, dose–response rela-
tionships, patient preferences, pharmaceutical therapy.
 
Introduction and Background
 
Nearly all therapeutic interventions involve a tradeoff
between potential benefit and harm. In most in-
stances, efficacy and toxicity both increase with dose
[1]. This is certainly the case in rheumatoid arthritis
and osteoarthritis, the therapeutic area that moti-
vated this research. The traditional treatment for pa-
tients with this condition includes nonsteroidal anti-
inflammatory drugs (NSAIDs), which are primarily
cyclooxygenase-type 1 (COX-1) inhibitors. Recently,
another pathway (called COX-2) has been used as
the basis for developing a new class of arthritis com-
pounds whose purpose is to provide pain relief simi-
lar to NSAIDs but with lower risk of a gastrointesti-
nal (GI) adverse event. Two COX-2 agents, celecoxib
and rofecoxib, have been approved recently in the
United States and elsewhere, with celecoxib the most
widely prescribed newly launched drug ever. With
such an array of therapeutic choices, drug developers,
clinicians, and patients need to examine efficacy/tox-
icity trade-offs.
For clinicians and patients especially, decision
making concerns not only purely medical parame-
ters, but also issues of patient preference that
might correlate with the impact of drugs on physi-
cal, mental, and social well-being. To reconcile
these conflicting considerations, one must acquire
both objective dose–response information about a
drug’s efficacy and toxicity, as well as subjective
patient-specific data on risk-benefit preferences.
 
Measurement of Dose–Response Relationship
 
Most drugs are administered in different dosages
within their therapeutic dose range, even for the
same disease indication. Pain treatment with
NSAIDs and COX-2 inhibitors is an example in
which the applied dose levels vary considerably
among patients. Data from pharmacokinetic and
pharmacodynamic studies of the drug develop-
ment process can be used to measure these effects
[2], and to formulate mathematical expressions of
dose–response behavior for both efficacy and tox-
icity [3]. Results are often expressed in terms of
the proportion of the population that achieves a
specified level of efficacy or toxicity outcome. In
antihypertensive drugs, for example, efficacy is de-
fined as the probability that a certain target blood
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pressure will be achieved at a certain dose, or that
blood pressure will drop by some prespecified
amount. In arthritis, efficacy might be measured in
a number of ways, including whether or not a pa-
tient achieves a specified threshold on a physi-
cian’s global assessment of pain. Toxicity is evalu-
ated by whether or not a patient experiences
Grade 3 or higher GI toxicity. For such binary-
valued patient outcomes, a maximal response is
eventually achieved (i.e., at most 100% of the
population) and a sigmoid curvature is observed.
The Hill equation [4] is one way of fitting sig-
moid dose-effect curves [5,6]. When it is applied
to binary variables, the model simplifies to
(1)
where 
 
p
 
 is the probability of drug effect, 
 
C
 
 is the
concentration, 
 
EC
 
50
 
 is the concentration eliciting
50% of the maximal response, and 
 

 
 is an expo-
nent that determines slope and steepness of the
curve. Logistic regression and probit models are
commonly used techniques of data analysis to as-
sess 
 
EC
 
50
 
 and the steepness parameter 
 

 
.
Drugs achieve objective tradeoffs between increas-
ing benefits and side-effects as doses increase. There-
fore, it is of general interest to assess how these bene-
fit-risk trades behave across the dose spectrum, how
they can be valued at any given dose, and how bene-
fit-risk trades compare among different drugs. With
the definition of binary valued outcomes (e.g., pain
relieved Yes/No, gastrointestinal bleeding Yes/No),
the meaning of increasing benefits and side-effects as
a function of dose is that the probability of both fa-
vorable and adverse events increases as higher doses
are applied. In the case of continuous or numerical
endpoints (e.g., blood pressure changes, depression
scores, changes in the number of blood cells), thresh-
olds or target values have to be defined (e.g., drops in
blood pressure by 30 mmHg) so that a decision can
be based on whether the threshold has been sur-
passed or the target achieved.
 
Benefit-Risk-Weighting in the Drug
Development Process
 
During earlier phases of drug development, re-
search concentrates not only on dose–response
modeling and identification of the maximally tol-
erated dose, but also on risk estimation for dose-
dependent toxicity [2,7–12]. Here the research
agenda is not guided by anticipation of prefer-
ences of decision-makers in the clinical setting.
The goal is to find a dose that satisfies both safety
and efficacy requirements as specified before the
p Cγ EC50
γ Cγ+( )⁄ ,=
 
trial [13]. A simple method to obtain tradeoff in-
formation is to specify, a priori, the maximum
toxicity rate that would be acceptable if the new
treatment were to produce 100% response; and
similarly to specify a minimum response rate that
would be acceptable if the treatment produced no
toxicities [14]. This method, in which the investi-
gators specify the efficacy-toxicity requirements
against which the drugs are then compared, can be
applied to dose-finding studies and for phase I/II
trials.
There is a lack of available techniques during
the drug development process to conduct relevant
benefit-to-risk assessments to determine the ac-
ceptability of a new drug across the dose range
used in the therapeutic setting [15]. Chuang-Stein
[16] developed a risk-adjusted benefit measure in
which the intensity of side-effects is quantified
through a set of scores that are summarized into
the risk component experienced by the individual.
This method weighs the risk component of a drug
according to its intensity, but it does not address
patients’ subjective values assigned to the expected
risk components. The approach described of sub-
tracting a multiple constant of the weighted risk
component from the expected crude benefit does
not consider that benefits and risks are interde-
pendent through their common dose, and that the
weighting scores for the risks might change de-
pending on the benefits achieved.
 
Weighing Benefits and Risks in the Clinical Setting
 
Measurement of patient well-being and preference
has become a focus of research in the area of clini-
cal decision making. Much of this work is moti-
vated by the observation that increased attention
to patients’ quality of life results in greater levels of
adherence to medication, satisfaction, and conform-
ance to the principle of informed consent [17–19].
One approach, Q-TWiST (Quality-adjusted Time
Without Symptoms of disease and Toxicity of
treatment), is a method that compares therapies in
terms of achieved survival and quality-of-life out-
comes [20–24]. Q-TWiST assesses both the likeli-
hood of a given health state and the quality
weighting to be assigned to that state. The result is
a preference measure that captures both quality of
life and time-linked data along a single index [25].
It has been shown that Q-TWiST is applicable,
provided survival is not seriously affected, when
treatment benefits must be balanced with the pa-
tient’s perception of acceptable toxic side-effects
and other long-term risks of treatment [26–28].
The challenge in implementing Q-TWiST is to de-
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fine clinically meaningful, time-linked health states
when survival is not affected, and to obtain reliable
measurements that apply across long periods of
time and over broad ranges of efficacy and toxicity
outcomes.
Another approach is multiattribute-utility the-
ory (MAUT), a method that is founded on the the-
ory of choice under uncertainty [29–33]. MAUT
provides a quantifiable summary score and uses
all available information on every defined, attain-
able health state. MAUT permits direct compari-
sons across health interventions and even across
therapeutic classes. For example, Eriksen and Keller
[34] developed a MAUT function to combine pref-
erences for efficacy and toxicity of a drug, and ap-
plied it to evaluation of antiglaucoma treatment.
However, an implicit assumption of MAUT is that
there is no preferential interaction, synergy, or
trade-off between levels of one attribute and fixed
levels of some other attribute. It is this assumption
(commonly referred to as “first-order utility in-
dependence”) that permits relative scaling when
a given attribute is held constant [35]. Thus, we
are forced to assume that relative preferences re-
main constant between two drugs with given ben-
efit outcomes as their toxicity level changes. From
a clinical perspective, this assumption may not ap-
ply since there is likely to be an interaction be-
tween preferences for efficacy at fixed levels of
toxicity [36,37]. Moreover, MAUT is cumber-
some. It demands a tremendous amount of pref-
erence elicitation from patients. To date, most
MAUT models have avoided the additional com-
plexity that would be imposed by including the
dose-dependence of drug efficacy and toxicity in
the definition of health states.
Another method, the probability tradeoff tech-
nique (PTT), also emerges from the theory of choice.
PTT involves a search for thresholds of indifference
[38–41]. Descriptive and probabilistic information
about potential benefits and side-effects of two ther-
apeutic alternatives are presented to patients and a
point is located where the patient is indifferent be-
tween the two options. The method can determine
how much benefit patients would require to accept a
new therapy, which carries a particular risk of toxic-
ity over an existing therapeutic intervention. The re-
sultant scale is idiosyncratic to the choice problem
posed and provides a relative measure of respon-
dents’ strength of preference for one option over an-
other [42]. The influence of framing effects [43–48]
has been explored for the PTT and has shown no
markedly different effects from positive or negative
frames [49,50]. Since surveys have shown that pa-
tients are able to deal with quantitative concepts of
probability [51], the PTT is practical and robust. Be-
cause it seems particularly well suited to the assess-
ment of patient preferences for drugs across dose
ranges, we selected it for further study in this paper.
 
Research Motivation and Goals
 
Using PTT, this paper describes a new method
that allows for evaluation of benefits and risks
while accounting for dose dependence of drug ef-
fects and preferences of decision-makers. The goal
is to promote a more informed choice of drugs
and dose levels by developing a simple tool for
combining subjective and objective information
about a drug. This is done by comparing directly
the exchange between efficacy and toxicity
achieved by a drug with the patients’ willingness
to accept tradeoffs between efficacy-toxicity pairs.
Such an index may be helpful to clinical decision-
makers in selecting an appropriate drug from
among different alternatives, and also to find a
dose that balances the need for sufficient efficacy
and acceptable toxicity. The model may also be
useful to pharmaceutical sponsors and the broader
medical community who wish to understand the
applicability and limitations to acceptance of their
therapeutic interventions.
The model is not intended as a method to iden-
tify an optimal dose that confers maximum benefit
on patients. It is understood—and reflected in our
model development—that different patients may
come to different conclusions about efficacy/toxic-
ity tradeoffs depending on a variety of factors, in-
cluding the extent of their disease and past thera-
peutic usage. The aim therefore is to consider
individual preferences and to derive an individu-
ally adjusted risk and preference index that is
grounded on reasonable, realistic expectations
comprised of the intrinsic weighting of the drug’s
performance, the perceived seriousness of the dis-
ease, and the expected severity of the drug’s side-
effects.
 
A Model for Dose-Dependent 
Benefit-Risk Evaluation
 
Efficacy-Toxicity Exchange Function of a Drug
 
The method begins by defining an efficacy-toxicity
exchange function based on available dose–response
curves for each drug. Monotonic curves for binary-
valued efficacy and toxicity outcomes are modeled
using the modified Hill equation—see equation (1).
Two distinct equations for each drug can be com-
bined such that gains in efficacy can be incorporated
 Dose-Adjusted Benefit-Risk Models
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with reductions in toxicity associated with different
doses:
Drug’s dose-dependent efficacy:
(2)
where 
 
P
 
de
 
 is the probability of the efficacy event,
 
D
 
 the common dose, 
 
U
 
 the EC
 
50
 
, and 
 

 
 the slope-
modulating exponential parameter of the efficacy
curve.
Drug’s dose-dependent toxicity:
(3)
where 
 
P
 
dt
 
 is the probability of the toxic event, 
 
W
 
the EC
 
50
 
, and 
 

 
 the slope-modulating exponential
parameter of the toxicity curve.
The drug’s efficacy-toxicity exchange curve is
found by solving equation (3) for 
 
D
 
 and substitut-
ing it into equation (2):
(4)
Any point on the exchange curve determines
the probabilities of benefits and risks that are as-
sociated with a certain dose, i.e., the additional
toxicity “cost” for each increment on the benefit
side that is achieved.
 
Patient Preferences over Efficacy-Toxicity Pairs
 
For the purpose of developing a new evaluation
method, efficacy/toxicity pairs are used that are
feasible from the efficacy-toxicity exchange func-
tion; namely, those that have been previously col-
lected in clinical trials and fall in the dose-range
used in the clinical setting. The PTT is used to as-
sess decision-makers’ preferences over different
combinations of expected efficacy and toxicity.
This information is used to develop preference
curves, illustrating patient willingness to accept
higher toxicity in exchange for a more effective
treatment (i.e., the efficacy they demand in order
to tolerate a higher toxicity) and, conversely, how
much efficacy patients are willing to give up when
treatment risks are reduced (i.e., to what extent
the toxicity has to be lowered if efficacy is de-
creased).
To provide logical upper and lower bounds to
the model, this study introduces “anchor points”
at both extremes of the tradeoff curve. These rep-
resent the limits beyond which there exist no clini-
cally pertinent efficacy-toxicity combinations. Us-
ing the approach of Conaway and Petroni [14],
Pde D
γ Uγ Dγ+( )⁄=
Pdt D
α Wα Dα+( )⁄=
Pde W
γ Pdt 1 Pdt–( )⁄[ ]
γ α⁄
 
U
 
γ W
 
γ Pdt 1 Pdt– ( )⁄[ ] 
γ α⁄+
 
( ).
 
⁄
=
 
patients are initially asked to mark the point
 
A
 
min
 
(
 
Eff
 
min
 
/0%) (i.e., the minimum efficacy re-
quired before any risk of toxicity will be tolera-
ble), and the point 
 
A
 
max
 
(100%/
 
Tox
 
max
 
) (i.e., the
maximum expected toxicity patients are willing to
endure for an expected efficacy probability of
100%). Thereafter, the PTT is used to evaluate
equally acceptable risk-benefit pairs between these
anchor points.
It is assumed that that the sample coordinates
belong to continuous curves. Hence, a host of
functional forms (e.g., polynomial equations with
different orders and hyperbolic functions) are used
to fit the patients’ required expected efficacy to
the maximum tolerable level of toxicity endured.
Standard statistical regression techniques are used
to obtain coefficients of the different mathemati-
cal models, and to assess goodness-of-fit of these
models to our data.
The simplest exchange-rate curve is a straight
line between 
 
A
 
min
 
 and 
 
A
 
max.
 
 This represents a lin-
early related preference function, where the pa-
tient’s required increase in expected efficacy is di-
rectly proportional to the increase in toxicity. The
curve can then be described as follows:
(5)
 
P
 
pe
 
 is the patient’s required probability of the
efficacy event and 
 
P
 
pt 
 
the accepted probability of
toxicity, whereas 
 
Eff
 
min
 
 and 
 
Tox
 
max 
 
are the values
as described for the two anchor points. It is rea-
sonable to assume a monotonic increase between
the anchor points, which implies that patients are
willing to assume more risk of harm in exchange
for a higher probability of benefit. A local extre-
mum at an interior point would contradict reason-
able behavior of patients to maximize the proba-
bility of benefits with minimum toxicity. Whether
patients exhibit increasing or diminishing mar-
ginal preferences for efficacy (i.e., concave or con-
vex preference curves) with respect to toxicity is
open to speculation, but it may reflect the extent
of their disease and past therapeutic experience
with certain drugs.
The curvature behavior can be adjusted to re-
flect a range of alternative assumptions in this re-
gard. The Hill equation models patient preference
curves for convex and concave behavior, which
must be adjusted through an appropriate coeffi-
cient plus intercept term (
 
Eff
 
min
 
). The shift parame-
ter (i.e., the 
 
EC
 
50
 
 equivalent in dose–response
curves) is fixed as the value 
 
Tox
 
max 
 
to yield the
general equation:
Ppe 1 Eff min–( ) Toxmax⁄[ ]Ppt Eff min.+=
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(6)
where 
 
P
 
pe
 
 and 
 
P
 
pt
 
 represent the pairs of risk-benefit
points, [2(1
 
 
 

 
 Eff
 
min
 
)] equals the coefficient, and
the exponent 
 

 
 determines if convexity or concav-
ity can be observed.
 
Risk- and Preference-Adjusted “Surplus Efficacy”
 
The final step in this model specification is to
combine objective information about a drug’s per-
formance with patients’ subjective preference func-
tions regarding potential treatments. At each dose
level, the drug has specified levels of toxicity and
efficacy. The preferences we have elicited permit
us to determine, for each patient, a personal (i.e.,
subjective) efficacy threshold. This threshold rep-
resents the minimum clinical benefit that the pa-
tient requires in exchange for enduring a given
level of toxicity. For some dose ranges, the drug’s
actual (objective) efficacy will fail to meet the pa-
tient’s (subjective) threshold; in other dose ranges,
the actual efficacy will exceed the patient’s mini-
mal requirement. These latter ranges—where the
patient determines that he or she is more than ade-
quately compensated for assuming a given level of
toxicity—are what is referred to as ranges of per-
ceived “surplus efficacy.” It should be noted that
there may be no reason to think that patients or
their doctors would aim to identify a unique drug
dose that maximizes surplus efficacy, since drug
and dosage selection are complex issues that ex-
tend beyond model-based criteria alone. However,
it is true that no patients would be pleased to ac-
cept a drug dose for which the surplus efficacy
value is negative. Therefore, it is useful to explore
dose ranges for which the surplus efficacy measure
assumes non-negative values.
The difference between the objective probabil-
ity of efficacy and the patient’s required efficacy at
a given toxicity can be expressed as:
(7)
for the linear model of the patient preference
curve, and, more generally, as
(8)
for the concave/convex preference curves. Here,
 
P
 
se 
 
denotes the surplus efficacy. In this formula-
Ppe 2 1 Eff min–( )[ ] Ppt
λ[ Toxmax
λ Ppt
λ+( ) ]⁄
Eff min,+
=
Pse W
γ Pt 1 Pt–( )⁄[ ]
γ α⁄ Uγ Wγ Pt 1 Pt–( )⁄[ ]
1 Ef f min–( ) Toxmax( )⁄[ ]Pt Eff min–
–+⁄=
Pse W
γ Pt 1 Pt–( )⁄[ ]
γ α⁄ Uγ Wγ Pt 1 Pt–( )⁄[ ]
2 1 Eff min–( )[ ] Pt
λ Toxmax
λ Pt
λ+( )⁄[ ]
–+⁄
Eff min–
=
 
tion, surplus efficacy is the difference between the
expected probabilities for the benefits of the drug,
 
P
 
de
 
, and the patient’s required probability of the
efficacy event, 
 
Ppe, at an accepted probability level
of toxicity Pse  Pde  Ppe.
Each point on the surplus efficacy function,
which we denote with the letter S, can then be
formed through pairs of the toxicity level Pt on the
X-axis and the surplus efficacy Pse on the Y-axis.
Since the surplus efficacy function has no meaning
outside the patient’s upper and lower bound or
outside the objective toxicity range, the functions
are defined for the toxicity interval [0%, Toxmax].
According to the Hill equation, a drug’s efficacy is
zero at zero dose and the maximum surplus effi-
cacy at Toxmax is zero. Therefore, all graphs range
between two extreme points: Si, which is defined
through the coordinates Si( Effmin/0), and St,
whose coordinates are at most St(0/Toxmax).
In order to find the dose range that renders pos-
itive surplus efficacy, the drugs’ objective efficacy
curves are converted to dose-dependent functions
and the patient’s preference curve is equivalently
related to these doses to express dose-dependent
surplus efficacy. For the linear model and the gen-
eral form for the concave/convex patient prefer-
ence curves, the equations are given by, respec-
tively:
(9)
and
(10)
The dose-dependent surplus efficacy function is
only defined for doses such that the expression
{D/(W  D)} takes on values in the toxicity in-
terval [0%, Toxmax].
Simulated Examples
Efficacy-Toxicity Exchange Functions for 
Simulated Drugs
To illustrate certain features of our model, we com-
pare the performance of seven hypothetical drugs
across a range of different patient preference func-
tions. The “drugs” and preference curves were re-
lated to show a broad range of therapeutic and pref-
erence characteristics. One can then readily see how
Pse D
γ Uγ Dγ+( ) 1 Eff min–( ) Toxmax⁄[ ]
Dα Wα Dα+( )⁄[ ] Eff min,–
–⁄=
Pse D
γ Uγ Dγ+( ) 2 1 Eff min–( )[ ]
1 Toxmax
λ– Toxmax
λ
Dα Wα Dα+( )⁄{ }λ
+(
)
⁄[
] Eff min–
–(
)
⁄=
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different characteristics affect the model-based val-
ues. Table 1 presents the dose–response functions
for seven simulated drugs. For ease of exposition
and comparison, we define a dose range from 0 to
30 standardized units. Figure 1 displays results from
applying the efficacy-toxicity exchange functions.
A drug can be defined as “dominating” when
its efficacy level is higher than that of another
drug for any toxicity level. Global dominance is
rarely observed; most exchange curves cross. In
Figure 1, drug2 dominates all other drugs. That is
because drug2 is a very safe and potent drug. It
achieves nearly 100% efficacy at a low dose level
without much toxicity. The development of side-
effects is delayed to higher doses when additional
gains in efficacy become incrementally small. By
contrast, drug1 exhibits steep early benefit re-
sponse, but additional gains can only be obtained
over a wider dose interval such that considerable
risks have to be borne. Drug1’s exchange curve
does not arch as steeply as drug2’s, even though
they have the same EC50 values for efficacy and
toxicity. They are the only two pharmaceutical
agents we consider that possess a purely convex
shape for their exchange functions, which implies
that the expected efficacy at any dose level is
higher than the expected toxicity level.
Drug1 and drug3 have the same toxicity response
behavior, but drug3’s efficacy curve is not as steep.
Except for the lowest toxicity level, drug3 provides
lower efficacy than drug1; beyond 95% efficacy, a
shift from concave to convex behavior indicates that
toxicity is increasing at a faster rate than efficacy.
Drug4 has the same dose-dependent efficacy as
drug1, but a different risk behavior. It has a higher
probability of side-effects than benefit at low doses
and therefore shows concavity up to efficacy and
toxicity levels of 30%. Drug1 is preferred up to an
efficacy level of 95%. Yet, drug4 eventually exceeds
drug1 in efficacy when one is willing to tolerate at
least a 50% chance of side-effects. Drug3 and drug4
have the same EC50s for efficacy and toxicity, but
different exponential parameters. If one is willing to
assume a 50% chance of therapeutic success, drug3
is dominant, because it is then accompanied by a
lower risk.
Drug5 offers virtually no gain in efficacy, but
considerable toxicity for most doses. At toxicity lev-
els of about 80%, one can observe a nearly vertical
efficacy increase. In the case where one is willing to
tolerate such a high probability of adverse events,
increasing doses can be applied to yield a high effi-
cacy without adding more risk. For drug 6 a reason-
able increase in efficacy with increasing dose can be
expected without much initial toxicity, but at effi-
cacy levels above 80%, one has to tolerate an in-
creasing rate of adverse events that eventually are
more likely to occur than are the benefits. As for its
efficacy- and toxicity-response curves, it seemed
similar to drug3 in that both have higher chances of
therapeutic success than toxicity for a wide dose
range. Yet, it performs much better than drug3 for
most levels of toxicity. Only when very high efficacy
levels are desired, is there a steep rise in toxicity. For
drug7, the increase in therapeutic benefits is nearly
paralleled by an equal increase in side-effects.
Figure 1 Efficacy-toxicity exchange curves
for simulated drugs.
Table 1 Overview of the mathematical formula for
the efficacy and toxicity curves used to simulate seven 
different drugs
Simulated 
drug
Efficacy
Pde  D/(U  D)
Toxicity 
Pdt  D/(W  D)
drug1 Pde  D4/(54  D4) Pdt  D4/(104  D4)
drug2 Pde  D10/(510  D10) Pdt  D10/(1010  D10)
drug3 Pde  D2/(52  D2) Pdt  D4/(104  D4)
drug4 Pde  D4/(54  D4) Pdt  D1/(101  D1)
drug5 Pde  D10/(2010  D10) Pdt  D1/(51  D1)
drug6 Pde  D4/(104  D4) Pdt  D17/(1517  D17)
drug7 Pde  D10/(1010  D10) Pdt  D10/(1110  D10)
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Patient Preference Functions
In order to examine the influence of subjective pref-
erences on surplus efficacy, we simulate two sets of
patient preference functions that differ with respect
to the anchor points, Amin and Amax. Each set encom-
passes five tradeoff curves that essentially have the
same behavior as discussed before: one linear pro-
portional exchange rate, two concave and two con-
vex tradeoff curves; also included is an extreme
case of concavity and convexity for illustrative pur-
poses. Again, these hypothetical curves were se-
lected to show the sensitivity of our model to pref-
erence alternatives. While one cannot expect to find
a concave preference curve very often in the clinical
setting (since concavity indicates that patients are
desperate to obtain efficacious treatment in ex-
change for high toxicity), it is conceivable that the
severity and/or duration of adverse effects is judged
to be minor/reversible so that subjects do not object
strongly to the occurrence of an adverse event. But
for most diseases and treatments, convex curvature
would be expected.
Patients’ subjective estimation of the severity of
the disease and the side-effects of treatment will
influence specification of the anchor points. Table
2 illustrates curves for a variety of different an-
chor point specifications. Figure 2 depicts the
preference functions that result from the first set
of anchor points. Subjects looking for a treatment
with some chance of success might indicate a very
low level Effmin for the anchor point Amin. Others
might be ready to accept a similarly modest Effmin,
if they see the potential side-effects as rather se-
vere and want to avoid them as much as possible.
Yet the same subjects might ask for a high Effmin, if
the disease is not experienced as very debilitating,
but the occurrence of side-effects is regarded as
bothersome or dangerous in comparison. A high
level can be expected for Toxmax, if the side-effects
are not regarded as very severe or if subjects are
anxious to find a highly efficacious treatment for
which they are willing to accept substantial toxic-
ity. Chemotherapy treatment for cancer diseases
might fall into this category. Conversely, subjects
may only be willing to accept a low level of maxi-
mum toxicity, if the side-effect is perceived as severe
in comparison to their perceived need for treatment.
Risk- and Preference-Adjusted Surplus
Efficacy Functions
To compare and contrast our model-based out-
comes, Figures 3 and 4 illustrate some surplus effi-
cacy outcomes for the linear patient preference
curve. In Figure 3, adjusted surplus efficacy is de-
picted as a function of toxicity; in Figure 4, it is
plotted with respect to dosage. Results for other
simulated preference curves look similar in shape.
In general, low doses produce unacceptably low
efficacy outcomes while high doses produce unac-
ceptably high rates of toxicity. In between, a bal-
ance is struck in which the drug surpasses the pa-
tient’s required minimal efficacy level. Ideally, a
drug should show convexity across the whole
range of observed dose-dependent toxicity levels.
But in some cases, concavity will be observed at
higher toxicity levels.
Figure 2 Different patient tradeoff curves
for first set of anchor points [Amin(0.6/0) &
Amax(1/0.8)].
Table 2 Mathematical description for the different patient 
preference curves for two different sets of anchor points
Anchor
Points
Preference
Function Mathematical Form
A1min(0.6/0) function1 Ppe  0.5* Ppt  0.6
A1max(1/0.8) function2 Ppe  0.8*[Ppt4/(0.84  Ppt4)]  0.6
function3 Ppe  0.8* [Ppt17/(0.817  Ppt17)]  0.6
function4 Ppe  0.8* [Ppt0.55/(0.80.55  Ppt0.55)]  0.6
function5 Ppe  0.8* [Ppt0.01/(0.80.01  Ppt0.01)]  0.6
A2min(0.4/0) function11 Ppe  (6/7)*Ppt  0.4
A2max(1/0.7) function22 Ppe  1.2*[Ppt4/(0.74  Ppt4)]  0.4
function33 Ppe  1.2* [Ppt17/(0.717  Ppt17)]  0.4
function44 Ppe  1.2*[Ppt0.55/(0.70.55  Ppt0.55)]  0.4
function55 Ppe  1.2* [Ppt0.01/(0.70.01  Ppt0.01)]  0.4
Dose-Adjusted Benefit-Risk Models 19
Figure 2 depicts delineated drugs that show
continuous convexity (drug1, drug2, and also
drug7), pharmaceutical treatments where curva-
ture changes in the course of the exchange func-
tion at different levels of toxicity (drug3, drug4,
and drug6), and also an example of a drug that re-
veals concave behavior (drug5). Those drugs that
have a steep hyperbolic concavity seem to be least
affected by the patient preference curves. For ex-
ample, drug2 has such a desirable efficacy/toxicity
profile that it produces surplus efficacy for any of
the simulated patient preference curves. Drug5 is
at the opposite end of the spectrum; there is no
dose level at which it produces an acceptable effi-
cacy/toxicity outcome. Most drugs, however, are
influenced by the shape of the preference function
as well as by the anchor points. In these cases, one
cannot easily conclude either uniform superiority
over other drugs or unambiguous positive surplus
efficacy over the entire dose range. For many
drugs, surplus efficacy values are spread over a
wide range of expected toxicity probabilities. Cor-
responding dose ranges with positive surplus effi-
cacy are given by the parabolic shape of the sur-
plus efficacy curve. Usually, the dose intervals are
narrow indicating that acceptable dose ranges to
achieve surplus efficacy are limited. Drug4, how-
ever, represents an exception: It is a compound
that produces surplus efficacy for most preference
functions at high levels of toxicity and across a
wide dose interval.
Discussion
We have developed a new model that allows
within- and between-drug comparisons of “surplus
efficacy.” A valuable feature of our method lies in
the fact that it combines objective clinical informa-
tion about a drug’s efficacy and toxicity with sub-
jective assessments of the risk-benefit trade-off. By
presenting risk-and preference-adjusted surplus effi-
cacy curves as a function of toxicity and dose, our
method may help individual decision-makers to
reconcile scientific information about a drug with
their personal preferences. It may also help deci-
sion-makers to make choices between drugs by
identifying therapies that involve the lowest possi-
ble toxicity for a given level of surplus efficacy. Our
model appears applicable to a wide spectrum of in-
terventions where side-effects are known to pose a
Figure 3 Surplus efficacy for linear prefer-
ence curve with respect to toxicity.
Figure 4 Surplus efficacy for linear prefer-
ence curve with respect to dose.
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serious concern and will affect patients’ willingness
to trade increased toxicity for increased efficacy. As
such, instances of repeated, longer-term, or even
chronic intake of therapeutic interventions (e.g., ar-
thritis) are promising areas of application.
Drugs are “penalized” that have high toxicity at a
given dose level. In this model, this is achieved by con-
trasting a patient’s willingness to endure toxicity in
exchange for a given benefit against a drug’s objective,
expected toxicity. Thus, at any dose level, a patient-
specific, preference-driven penalty score is assigned to
the expected benefit. By contrast, Chuang-Stein em-
ploys a benefit-less-risk analysis [16] where intensity
grades of side-effects are quantified through scoring
methods and the additional decision has to be made
how much penalty the side-effects ought to exert.
This study’s method can be applied in the clini-
cal setting, provided data are available regarding
efficacy and toxicity across a range of doses. In
addition, patient preference information is needed
that describes the trade-off of increased risk for in-
creased efficacy. Patient preferences are elicited
via the PTT framework and should be linked to
the relevant anchor points. As for the PTT elicita-
tion task, the question of consistency and reliabil-
ity must be addressed. Framing, as discussed in the
introduction, concerns two alternatives of empha-
sizing gains (i.e., the probability of beneficial re-
sponse and the chance of no side-effects), or losses
(i.e., chances of no beneficial effect and the probabil-
ity of side-effects). A balanced format with emphasis
on both gains and losses will reduce a potential bias.
Through initial specification of anchor points, pa-
tients are made aware of considering changes in both
efficacy and toxicity probabilities. Probability esti-
mates are often biased towards the initial value
where the task started [52,53]. The potential bias
of the initial value and the direction taken can be re-
duced by making patients aware of the constraint
that a possible path starting at one side has to end
up at the other extreme. Thus, two anchor points
were specified in our modeling process. It is also
necessary for the comparison with the drugs’ effi-
cacy-toxicity exchange functions to relate the an-
chor points and the preference curve to realistically
achievable benefit-risk pairs. That is, patients need
an estimate of risk-benefit combinations that stan-
dard treatments for the disease can actually achieve.
The precise specification of an optimal dose
from a clinical standpoint cannot be addressed us-
ing this approach. The method does not adjust the
magnitude of surplus efficacy for the value this ad-
ditional benefit brings to the patient. For this rea-
son, it cannot be assumed that the toxicity or dose
level where the highest surplus efficacy level is
achieved in this model will automatically translate
to be the uniquely optimal choice for the patient.
The patient may obtain equivalent satisfaction
from any number of doses located within the posi-
tive surplus efficacy range. If a patient’s preference
curve represents an indifference curve, for exam-
ple, then that patient ought to be willing to ex-
change any point on the curve as equally valuable.
Even if this is a reasonable assumption, the
method of finding risk- and preference-adjusted
surplus efficacy does not allow determination of
an optimal dose that will yield the maximum sur-
plus benefit to the patient.
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